Ascletis Pharma Inc. announced that it has received CNY 700 million in series B round of funding led by existing investor C-Bridge Capital, a fund managed by C-Bridge Capital Partners LLC on January 3, 2017. The transaction involved participation from existing investors Goldman Sachs Group, Merchant Banking Division, Tasly Pharmaceutical Group Co., Ltd. (SHSE:600535), new investors Qianhai Equity Investment FOF, a fund managed by Shenzhen Capital Group Co., Ltd., WTT Investment, and FOCUS Media Jiangnanchun Foundation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 HKD | 0.00% |
|
+4.00% | -28.77% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.77% | 135M | |
+7.47% | 100B | |
+11.97% | 42.34B | |
-11.76% | 32.76B | |
+79.34% | 29.46B | |
-12.20% | 16.31B | |
+4.00% | 14.39B | |
-1.90% | 12.23B | |
+178.17% | 10.47B | |
+1.80% | 8.97B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Inc. announced that it has received CNY 700 million in funding from C-Bridge Capital Partners LLC, Goldman Sachs Group, Merchant Banking Division, Tasly Pharmaceutical Group Co., Ltd., Shenzhen Capital Group Co., Ltd.